ML signed the awaited deal for its inhaler drug last week. expect the announcement in a week.

If someone is going to make a bid for this company they better do it soon before too much good news comes out.DYOR

it's about time we had some positive
news we've waited long enough,
lets hope it has been worth waiting for
and reflects in the sp
all the best

HUSTLER

No buyers here. Good news and they all sell !!!

This stock is realy spooking me Troys
years of crap then good news and everyone sells
can only hope the new management shakes it by the
throat over time. Just hope they don't come back
to investors for yet more funding.

regards HUSTLER

ML Laboratories PLC (the 'Company')

Notification of Major Interests in Shares

Section 198 to 202 Companies Act 1985

The Company received a notification today from AVIVA plc on behalf of itself and
Morley Fund Management Limited informing it that following share purchases of
1,000,000 shares on 16 March 2005, they have in interest in 23,392,806 shares
representing 10.23% of the Company's issued ordinary share capital.

18 March 2005

M.L. Laboratories PLC
22 March 2005


For Immediate Release 22 March 2005

ML Laboratories plc



Marketing Approvals Received for Two Separate Asthma Compounds in First European
Market



ML Laboratories plc (MLB.L) has received news from its licensing partner that
its innovative dry powder inhaler, Clickhaler(R), has been granted two marketing
approvals in its first European market for use with budesonide and formoterol
respectively, two widely-prescribed asthma therapies. This is the first country
in Europe to approve these two Clickhaler products and applications in other
European markets are progressing.



The budesonide and formoterol Clickhaler products were licensed by ML to an
undisclosed major pharmaceutical partner in September 2002. Under the terms of
this agreement, ML receives milestone payments on receipt of marketing
approvals, followed by further milestones on product launches and double digit
royalties on sales.



Sales of comparable budesonide products in Europe total 200 million while the
European market for comparable formoterol products is estimated at more than
100 million. Both Clickhaler products will be launched at the earliest
opportunity.



Clickhaler products are now approved in one or more European countries for
salbutamol, beclomethasone, budesonide and formoterol, with the Meptin
Clickhaler (Otsuka's procaterol) recently approved in Japan.



Paul Ballington, Director of Marketing and Business Development, commented:



'Clickhaler has now been approved with a number of asthma treatments, each
representing a substantial market opportunity. The European markets for both
budesonide and formoterol are predominantly in dry powder delivery devices and
we believe that Clickhaler's ease of use and reliability will enable it to gain
a significant share of these markets.'





Contacts:


ML Laboratories plc Tel: +44 (0)1727 837 341
Paul Ballington
Managing Director of Innovata Biomed

Financial Dynamics Tel: +44 (0)7747 602 739 / (0) 20 7831 3113
David Yates / Sarah MacLeod





Notes to Editors



ML Laboratories plc

ML operates through two divisions, both focused on the development of high value
pharmaceutical products - Innovata Biomed, the Group's respiratory division, and
ML Pharmaceuticals, a pharmaceutical product development business.



Innovata Biomed (IB) is a leading independent provider of inhaled drug delivery
technologies to the global pharmaceutical industry, formulating dry powders and
developing proprietary inhaler systems through to full industrialisation. IB's
proven delivery technologies are available for proof-of-principle testing and as
fast-to-market drug delivery solutions. It has a number of respiratory products
both in development and marketed by pharmaceutical company licensees including
Celltech, Otsuka and Pliva.



ML's pharmaceutical product development division, ML Pharmaceuticals, contains
both marketed products and new therapeutics in clinical development. Marketed
products include Extraneal for the treatment of renal failure, which has been
licensed to Baxter, and Adept for the reduction of adhesions in abdominal
surgery, which is marketed by Shire Pharmaceuticals in Europe. New therapeutic
products in development include Alpharen, a phosphate binder to assist the
management of kidney failure, treatments for prostate and skin cancer and a pain
management compound.


This information is provided by RNS
The company news service from the London Stock Exchange

Does any one know what the milestone payments are?

LONDON (AFX) - Pharmaceuticals group ML Laboratories PLC said its licensing partner for the Clickhaler dry powder inhaler, which it hasn't named, has announced the inhaler has won approval in the Netherlands for use with asthma treatments budesonide and formoterol.

The group said this is the first country in Europe to approve these two Clickhaler products and added that applications in other European markets are progressing.

The budesonide and formoterol Clickhaler products were licensed out by ML to an undisclosed 'major pharmaceutical partner' in September 2002. ML gets milestone payments on receipt of marketing approvals and then again on product launches, together with royalties on sales.

ML said sales of comparable budesonide products in Europe total are worth 200 mln stg while the European market for comparable formoterol products is estimated at some 100 mln stg.

The company said Clickhaler products are now approved in one or more European countries for use with salbutamol and beclomethasone as well as those announced today.

newsdesk@afxnews.com

cw

ML Laboratories plc
Appointment of Advisers


The Board of ML Laboratories plc is pleased to announce the appointment of new
advisers. Code Securities Limited is appointed as Financial Adviser and Broker
to the Company, Jones Day is appointed as Legal Adviser and Financial Dynamics
is appointed as Financial PR adviser. All appointments are effective
immediately.

M.L. Laboratories PLC
22 March 2005

Letter to: ML Laboratories PLC
Dated: 21 March 2005

ML LABORATORIES PLC (THE 'COMPANY') - SEDOL 0555470

This notification supersedes our previous notification to you dated 17 March
2005 and is prompted by purchases totalling 2,500,000 on 18 March 2005.

This notification relates to issued ordinary shares of GBP0.01 each in the
capital of the Company (the 'shares') and is given in fulfilment of the
obligations imposed by sections 198 to 202 of the Companies Act 1985 (the
'Act').

1. Notification on behalf of Morley Fund Management Limited (a subsidiary of
Aviva plc).

1.1 We hereby notify you on behalf of Morley Fund Management Limited that
immediately after the time when the obligation to make this notification
arose Morley Fund Management Limited were interested in 26,392,806 shares.

1.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Morley Fund Management Limited.

2. Notification on behalf of Aviva plc.

2.1 We hereby notify you on behalf of Aviva plc that immediately after the
time when the obligation to make this notification arose Aviva plc were
interested in 26,392,806 shares giving the Aviva group a total percentage
interest in the shares of 11.54%.

2.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Aviva plc.

From: Aviva PLC


APPENDIX: MORLEY FUND MANAGEMENT LIMITED

REGISTERED HOLDERS NUMBER OF SHARES HELD
BNY Norwich Union Nominees Ltd 845,163 (Material)
Chase GA Group Nominees Ltd 4,656,093 (Material)
CUIM Nominee Ltd 1,506,596 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,384,954


TOTAL PERCENTAGE INTEREST OF MORLEY FUND MANAGEMENT LIMITED: 11.54%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703


APPENDIX: AVIVA PLC

REGISTERED HOLDERS NUMBER OF SHARES HELD
BNY Norwich Union Nominees Ltd 845,163 (Material)
Chase GA Group Nominees Ltd 4,656,093 (Material)
CUIM Nominee Ltd 1,506,596 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,384,954


TOTAL PERCENTAGE INTEREST OF AVIVA PLC: 11.54%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703



This information is provided by RNS
The company news service from the London Stock Exchange

Loads of news. No movement on SP yet. Must be something else holding these back? LOL

If the good news keeps coming
eventually the sp will have to respond.
Lets hope the new management will deliver
in time, only hope that is not far away.
The best news other than marketing approvals
would be a maiden profit this would reduce the
fear of the company coming back to shareholders for
more funds, and rebuild confidence this would almost
certainly boost the sp.
all the best
hustler

M.L. Laboratories PLC
23 March 2005


Letter to: ML Laboratories PLC
Dated: 23 March 2005

ML LABORATORIES PLC (THE 'COMPANY') - SEDOL 0555470

This notification supersedes our previous notification to you dated 21 March
2005 and is prompted by purchases totalling 1,000,000 on 22 March 2005.

This notification relates to issued ordinary shares of GBP0.01 each in the
capital of the Company (the 'shares') and is given in fulfilment of the
obligations imposed by sections 198 to 202 of the Companies Act 1985 (the
'Act').

1. Notification on behalf of Morley Fund Management Limited (a subsidiary of
Aviva plc).

1.1 We hereby notify you on behalf of Morley Fund Management Limited that
immediately after the time when the obligation to make this notification
arose Morley Fund Management Limited were interested in 27,892,806 shares.

1.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Morley Fund Management Limited.

2. Notification on behalf of Aviva plc.

2.1 We hereby notify you on behalf of Aviva plc that immediately after the
time when the obligation to make this notification arose Aviva plc were
interested in 27,892,806 shares giving the Aviva group a total percentage
interest in the shares of 12.20%.

2.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Aviva plc.

From: Aviva PLC


APPENDIX: MORLEY FUND MANAGEMENT LIMITED

REGISTERED HOLDERS NUMBER OF SHARES HELD

BNY Norwich Union Nominees Ltd 1,003,832 (Material)
Chase GA Group Nominees Ltd 5,528,317 (Material)
CUIM Nominee Ltd 1,789,440 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,571,217


TOTAL PERCENTAGE INTEREST OF MORLEY FUND MANAGEMENT LIMITED: 12.20%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703


APPENDIX: AVIVA PLC

REGISTERED HOLDERS NUMBER OF SHARES HELD

BNY Norwich Union Nominees Ltd 1,003,832 (Material)
Chase GA Group Nominees Ltd 5,528,317 (Material)
CUIM Nominee Ltd 1,789,440 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,571,217


TOTAL PERCENTAGE INTEREST OF AVIVA PLC: 12.20%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703



This information is provided by RNS
The company news service from the London Stock Exchange

M.L. Laboratories PLC
04 April 2005

For Immediate Release



ML Laboratories PLC

Trading Outlook



St Albans, UK, 4 April 2005 -- ML Laboratories PLC (LSE: MLB) provides guidance
on the trading outlook for the financial year.



In line with the Board's expectations, the Group expects to achieve a positive
trading result for the year ending 30 September 2005 before the impact of
restructuring and associated costs.



Following the appointments of the Executive Chairman and Chief Executive
announced on 3 March, the Board has commenced a strategic review of the business
in which it will seek to cut costs and streamline operations. As a result, it is
expected that after one off restructuring costs, the majority of which will be
non-cash write-offs of impaired tangible and intangible assets, the Group will
be loss-making in the current financial year.



Results of the strategic review and further guidance on full year earnings will
be provided with the interim results to be announced in June 2005.



Contacts:


ML Laboratories
Kieran Murphy, Chief Executive Officer Tel: 01727 739300
Peter Shennan, Finance Director Tel: 01925 844700

Financial Dynamics
Sarah MacLeod / David Yates Tel: 020 7831 3113





Notes to Editors



ML operates through two divisions, both focused on the development of high value
pharmaceutical products - Innovata Biomed, the Group's respiratory division, and
ML Pharmaceuticals, a pharmaceutical product development business.



Innovata Biomed (IB) is a leading independent provider of inhaled drug delivery
technologies to the global pharmaceutical industry, formulating dry powders and
developing proprietary inhaler systems through to full industrialisation. IB's
proven delivery technologies are available for proof-of-principle testing and as
fast-to-market drug delivery solutions. It has a number of respiratory products
both in development and marketed by pharmaceutical company licensees including
Celltech, Otsuka and Pliva.



ML's pharmaceutical product development division, ML Pharmaceuticals, contains
both marketed products and new therapeutics in clinical development. Marketed
products include Extraneal for the treatment of renal failure, which has been
licensed to Baxter, and Adept for the reduction of adhesions in abdominal
surgery, which is marketed by Shire Pharmaceuticals in Europe. New therapeutic
products in development include Alpharen, a phosphate binder to assist the
management of kidney failure, treatments for prostate and skin cancer and a pain
management compound.




This information is provided by RNS
The company news service from the London Stock Exchange

Now give us some good news!!!!

And here is the good news

M.L. Laboratories PLC
04 April 2005


ML Laboratories PLC


Presents Phase III Trial Data on Adept(R) and Hosts Symposium on Reduction of
Surgical Adhesions at London Gynecologic Endoscopy Congress


St Albans, UK, 4 April 2005 - ML Laboratories PLC (LSE: MLB) is today presenting
data from the first ever double-blind, randomised, study in abdominal surgery
with Adept at the 14th Annual Congress of the International Society of
Gynecologic Endoscopy in London. The Company is also hosting a symposium on the
need for improved adhesion reduction agents in abdominal surgery, with
presentations from some of the world's leading opinion leaders in gynaecological
adhesions.


Use of many available adhesion reduction agents has generally been limited due
to cost, safety issues and technical difficulties, especially in abdominal
surgery. Available in Europe since 2000, Adept is a 4% icodextrin solution that
has been used in adhesion reduction in over 100,000 surgical patients. Benefits
over existing treatments include cost-effectiveness and ease of use,
particularly where there have been deficiencies with other anti-adhesion agents.


Prof Gere diZerega, MD, Professor of Obstetrics and Gynecology at the Los
Angeles County University of Southern California, USA, will present data from
the 440 patient, pivotal Phase III trial, which examined the efficacy of Adept
in a comparative study. The results of this landmark study will be submitted to
the Food and Drug Administration for US marketing authorisation in the coming
months.


Geoffrey Trew, MRCOG, Consultant in Reproductive Medicine and Surgery at
Hammersmith Hospital, London, UK, will consider the risk of adhesion-related
problems to a patient and the practical implementation of adhesion prevention in
routine surgery.


Adrian Lower, FRCOG, Consultant Gynaecologist for the London Clinic, London, and
Medical Director of the ISIS Fertility Centre, Colchester, UK will review recent
findings from an epidemiological study, which identifies gynaecological surgical
procedures, related diseases and other factors defining high-risk populations at
whom anti-adhesion strategies should be targeted routinely.


Commenting, Geoff Trew, MRCOG, said:


'This is biggest and best constructed study ever undertaken with an
anti-adhesion agent and I find the results very exciting. Adept is one of the
most important surgical device developments in the last decade, filling a niche
where there is currently really nothing at all. It is safe, easy to use and
inexpensive, and these study results have confirmed what many people suspected -
that is an effective agent.'


A copy of the presentations from today's symposium is available on request.



Contacts:


ML Laboratories plc Tel: +44 (0)1727 837 341

Paul Ballington, Director of Marketing & Business Development


Financial Dynamics Tel: +44 (0) 20 7831 3113

Sarah MacLeod



Notes to Editors


ML Laboratories plc

ML operates through two divisions, both focused on the development of high value
pharmaceutical products - Innovata Biomed, the Group's respiratory division, and
ML Pharmaceuticals, a pharmaceutical product development business.


Innovata Biomed (IB) is a leading independent provider of inhaled drug delivery
technologies to the global pharmaceutical industry, formulating dry powders and
developing proprietary inhaler systems through to full industrialisation. IB's
proven delivery technologies are available for proof-of-principle testing and as
fast-to-market drug delivery solutions. It has a number of respiratory products
both in development and marketed by pharmaceutical company licensees including
Celltech, Otsuka and Pliva.


ML's pharmaceutical product development division, ML Pharmaceuticals, contains
both marketed products and new therapeutics in clinical development. Marketed
products include Extraneal for the treatment of renal failure, which has been
licensed to Baxter, and Adept for the reduction of adhesions in abdominal
surgery, which is marketed by Shire Pharmaceuticals in Europe. New therapeutic
products in development include Alpharen, a phosphate binder to assist the
management of kidney failure, treatments for prostate and skin cancer and a pain
management compound.



This information is provided by RNS

Now we should see the sp head north. LOL

Like the comment Adept is one of the
most important surgical developments in the last
decade.
If that dosen't move the sp nothing will.

Even though it is disapointing the maiden
profit will not come this time round.
Lets hope the news will override the disapointment.
It's about time we had somthing to celebrate.

hustler

Lots in the pipeline - check it out

http://www.mllabs.com/pipeline.htm#